Cook targets non-coronary DES market with Angiotech deal
This article was originally published in Clinica
Executive Summary
Cook, a co-licensee of Angiotech Pharmaceuticals' paclitaxel-eluting stent technology, is to move out of the competitive coronary vascular hothouse and into the peripheral vascular and gastrointestinal markets. The move has opened up an opportunity for Boston Scientific, the other co-licensee, to hold exclusive rights to Angiotech's technology for coronary stent use.